Update README.md
Browse files
README.md
CHANGED
|
@@ -10,140 +10,56 @@ tags:
|
|
| 10 |
size_categories:
|
| 11 |
- 10K<n<100K
|
| 12 |
---
|
| 13 |
-
|
| 14 |
-
|
| 15 |
-
|
| 16 |
-
|
| 17 |
-
|
| 18 |
-
|
| 19 |
-
|
| 20 |
-
|
| 21 |
-
|
| 22 |
-
|
| 23 |
-
|
| 24 |
-
|
| 25 |
-
|
| 26 |
-
|
| 27 |
-
- **Curated by:** [More Information Needed]
|
| 28 |
-
- **Funded by [optional]:** [More Information Needed]
|
| 29 |
-
- **Shared by [optional]:** [More Information Needed]
|
| 30 |
-
- **Language(s) (NLP):** [More Information Needed]
|
| 31 |
-
- **License:** [More Information Needed]
|
| 32 |
-
|
| 33 |
-
### Dataset Sources [optional]
|
| 34 |
-
|
| 35 |
-
<!-- Provide the basic links for the dataset. -->
|
| 36 |
-
|
| 37 |
-
- **Repository:** [More Information Needed]
|
| 38 |
-
- **Paper [optional]:** [More Information Needed]
|
| 39 |
-
- **Demo [optional]:** [More Information Needed]
|
| 40 |
-
|
| 41 |
-
## Uses
|
| 42 |
-
|
| 43 |
-
<!-- Address questions around how the dataset is intended to be used. -->
|
| 44 |
-
|
| 45 |
-
### Direct Use
|
| 46 |
-
|
| 47 |
-
<!-- This section describes suitable use cases for the dataset. -->
|
| 48 |
-
|
| 49 |
-
[More Information Needed]
|
| 50 |
-
|
| 51 |
-
### Out-of-Scope Use
|
| 52 |
-
|
| 53 |
-
<!-- This section addresses misuse, malicious use, and uses that the dataset will not work well for. -->
|
| 54 |
-
|
| 55 |
-
[More Information Needed]
|
| 56 |
-
|
| 57 |
-
## Dataset Structure
|
| 58 |
-
|
| 59 |
-
<!-- This section provides a description of the dataset fields, and additional information about the dataset structure such as criteria used to create the splits, relationships between data points, etc. -->
|
| 60 |
-
|
| 61 |
-
[More Information Needed]
|
| 62 |
-
|
| 63 |
-
## Dataset Creation
|
| 64 |
-
|
| 65 |
-
### Curation Rationale
|
| 66 |
-
|
| 67 |
-
<!-- Motivation for the creation of this dataset. -->
|
| 68 |
-
|
| 69 |
-
[More Information Needed]
|
| 70 |
-
|
| 71 |
-
### Source Data
|
| 72 |
-
|
| 73 |
-
<!-- This section describes the source data (e.g. news text and headlines, social media posts, translated sentences, ...). -->
|
| 74 |
-
|
| 75 |
-
#### Data Collection and Processing
|
| 76 |
-
|
| 77 |
-
<!-- This section describes the data collection and processing process such as data selection criteria, filtering and normalization methods, tools and libraries used, etc. -->
|
| 78 |
-
|
| 79 |
-
[More Information Needed]
|
| 80 |
-
|
| 81 |
-
#### Who are the source data producers?
|
| 82 |
-
|
| 83 |
-
<!-- This section describes the people or systems who originally created the data. It should also include self-reported demographic or identity information for the source data creators if this information is available. -->
|
| 84 |
-
|
| 85 |
-
[More Information Needed]
|
| 86 |
-
|
| 87 |
-
### Annotations [optional]
|
| 88 |
-
|
| 89 |
-
<!-- If the dataset contains annotations which are not part of the initial data collection, use this section to describe them. -->
|
| 90 |
-
|
| 91 |
-
#### Annotation process
|
| 92 |
-
|
| 93 |
-
<!-- This section describes the annotation process such as annotation tools used in the process, the amount of data annotated, annotation guidelines provided to the annotators, interannotator statistics, annotation validation, etc. -->
|
| 94 |
-
|
| 95 |
-
[More Information Needed]
|
| 96 |
-
|
| 97 |
-
#### Who are the annotators?
|
| 98 |
-
|
| 99 |
-
<!-- This section describes the people or systems who created the annotations. -->
|
| 100 |
-
|
| 101 |
-
[More Information Needed]
|
| 102 |
-
|
| 103 |
-
#### Personal and Sensitive Information
|
| 104 |
-
|
| 105 |
-
<!-- State whether the dataset contains data that might be considered personal, sensitive, or private (e.g., data that reveals addresses, uniquely identifiable names or aliases, racial or ethnic origins, sexual orientations, religious beliefs, political opinions, financial or health data, etc.). If efforts were made to anonymize the data, describe the anonymization process. -->
|
| 106 |
-
|
| 107 |
-
[More Information Needed]
|
| 108 |
-
|
| 109 |
-
## Bias, Risks, and Limitations
|
| 110 |
-
|
| 111 |
-
<!-- This section is meant to convey both technical and sociotechnical limitations. -->
|
| 112 |
-
|
| 113 |
-
[More Information Needed]
|
| 114 |
-
|
| 115 |
-
### Recommendations
|
| 116 |
-
|
| 117 |
-
<!-- This section is meant to convey recommendations with respect to the bias, risk, and technical limitations. -->
|
| 118 |
|
| 119 |
-
|
| 120 |
|
| 121 |
-
##
|
| 122 |
|
| 123 |
-
|
|
|
|
| 124 |
|
| 125 |
-
**
|
| 126 |
|
| 127 |
-
|
| 128 |
|
| 129 |
-
|
|
|
|
| 130 |
|
| 131 |
-
|
| 132 |
|
| 133 |
-
##
|
| 134 |
|
| 135 |
-
|
|
|
|
| 136 |
|
| 137 |
-
[
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 138 |
|
| 139 |
-
|
|
|
|
| 140 |
|
| 141 |
-
|
| 142 |
|
| 143 |
-
|
|
|
|
|
|
|
|
|
|
| 144 |
|
| 145 |
-
[More Information Needed]
|
| 146 |
|
| 147 |
-
## Dataset Card Contact
|
| 148 |
|
| 149 |
-
[More Information Needed]
|
|
|
|
| 10 |
size_categories:
|
| 11 |
- 10K<n<100K
|
| 12 |
---
|
| 13 |
+
---
|
| 14 |
+
pretty_name: MedInjection-FR — Translated Subset
|
| 15 |
+
language:
|
| 16 |
+
- fr
|
| 17 |
+
license: mit
|
| 18 |
+
task_categories:
|
| 19 |
+
- translation
|
| 20 |
+
- question-answering
|
| 21 |
+
size_categories:
|
| 22 |
+
- 300K<n<500K
|
| 23 |
+
---
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 24 |
|
| 25 |
+
# MedInjection-FR — Translated Subset 🌍
|
| 26 |
|
| 27 |
+
## Summary
|
| 28 |
|
| 29 |
+
The **Translated** component of **MedInjection-FR** adapts large-scale **English biomedical instruction datasets** into French through high-quality automatic translation.
|
| 30 |
+
It represents the most extensive part of the collection, comprising **418 061 instruction–response pairs**, and provides a bridge between English biomedical resources and French medical instruction tuning.
|
| 31 |
|
| 32 |
+
This subset was designed to ensure **broad domain coverage** while maintaining **semantic and linguistic fidelity**, enabling robust cross-lingual transfer and comparative evaluation between native, synthetic, and translated supervision sources.
|
| 33 |
|
| 34 |
+
## Motivation
|
| 35 |
|
| 36 |
+
The scarcity of large-scale French biomedical instruction data limits the capacity of LLMs to generalize across complex medical domains.
|
| 37 |
+
To address this, the Translated subset leverages **trusted English benchmarks**—spanning medicine, biology, psychology, and clinical knowledge—and systematically translates them into French while preserving the structure of instruction–response pairs.
|
| 38 |
|
| 39 |
+
This allows for rigorous experiments on **cross-lingual instruction adaptation**, complementing the native and synthetic subsets of MedInjection-FR.
|
| 40 |
|
| 41 |
+
## Composition
|
| 42 |
|
| 43 |
+
To expand data coverage while maintaining linguistic fidelity, a large collection of **English biomedical instruction datasets** was translated into French using **[Gemini 2.0 Flash](https://blog.google/products/gemini/google-gemini-2/)** and **[GPT-4o-mini](https://openai.com/research/gpt-4o)**.
|
| 44 |
+
The translated component comprises **418 061 instruction–response pairs** derived from several established English resources:
|
| 45 |
|
| 46 |
+
- **[MedQA](https://arxiv.org/abs/2009.13081)** – medical board–style multiple-choice QA.
|
| 47 |
+
- **[PubMedQA](https://aclanthology.org/D19-1259/)** – factoid biomedical QA from PubMed abstracts.
|
| 48 |
+
- **[MedMCQA](https://proceedings.mlr.press/v174/pal22a.html)** – clinical multiple-choice QA covering 21 medical specialties.
|
| 49 |
+
- **[MMLU](https://arxiv.org/abs/2009.03300)** – six medical categories (e.g., anatomy, clinical knowledge, college biology, college medicine, medical genetics, professional medicine).
|
| 50 |
+
- **[K-QA](https://aclanthology.org/2024.bionlp-1.22/)** – open-ended biomedical question answering for reasoning over scientific text.
|
| 51 |
+
- **[MMLU-PRO](https://arxiv.org/abs/2406.01574)** – professional-level QA across psychology, biology, and health domains.
|
| 52 |
+
- **[MedXpertQA](https://arxiv.org/abs/2501.18362)** – clinical reasoning dataset focusing on multi-hop and expert-level diagnostic questions.
|
| 53 |
|
| 54 |
+
To assess translation quality, outputs were evaluated using **BLEU** and **COMET** on the **[WMT 2024 Biomedical Translation Task](https://www.statmt.org/wmt24/biomedical-task.html)** corpus \cite{neves-etal-2024-findings}.
|
| 55 |
+
Both *Gemini 2.0 Flash* and *GPT-4o-mini* achieved results comparable to the **best WMT 2024 system**, indicating that the Translated subset maintains high semantic fidelity and linguistic quality suitable for French biomedical instruction tuning.
|
| 56 |
|
| 57 |
+
## Use
|
| 58 |
|
| 59 |
+
Intended for:
|
| 60 |
+
- Fine-tuning French biomedical LLMs with translated instruction–response pairs
|
| 61 |
+
- Studying cross-lingual transfer and translation quality in instruction tuning
|
| 62 |
+
- Evaluating the interplay between translation fidelity and domain adaptation performance
|
| 63 |
|
|
|
|
| 64 |
|
|
|
|
| 65 |
|
|
|